Inhibition of microsomal triglyceride transfer protein: Another mechanism for drug-induced steatosis in mice
- 1 July 2003
- journal article
- Published by Ovid Technologies (Wolters Kluwer Health) in Hepatology
- Vol. 38 (1), 133-140
- https://doi.org/10.1053/jhep.2003.50309
Abstract
Although many steatogenic drugs inhibit mitochondrial fatty acid β‐oxidation, limited information is available on possible effects on hepatic lipoprotein secretion. In the endoplasmic reticulum (ER) lumen, microsomal triglyceride transfer protein (MTP) lipidates apolipoprotein B (Apo B), to form triglyceride (TG)‐rich very low density lipoprotein (VLDL) particles, which follow vesicular flow to the plasma membrane to be secreted, whereas incompletely lipidated Apo B particles are partly degraded. We studied hepatic MTP activity, the lipoproteins present in the ER lumen, and hepatic lipoprotein secretion 4 hours after administration of a single dose of amineptine (1 mmol/kg), amiodarone (1 mmol/kg), doxycycline (0.25 mmol/kg), tetracycline (0.25 mmol/kg), tianeptine (0.5 mmol/kg), or pirprofen (2 mmol/kg) in mice. These various doses have been shown previously to markedly inhibit fatty acid oxidation after a single dose, and to trigger steatosis either after repeated doses (doxycycline) or a single dose (other compounds) in mice. In the present study, amineptine, amiodarone, pirprofen, tetracycline, and tianeptine, but not doxycycline, inhibited MTP activity in vitro, decreased ex vivo MTP activity in the hepatic homogenate of treated mice, decreased TG in the luminal VLDL fraction of hepatic microsomes of treated mice, and decreased in vivo hepatic lipoprotein secretion (TG and Apo B). In conclusion, several steatogenic drugs inhibit not only mitochondrial β‐oxidation, as previously shown, but also MTP activity, Apo B lipidation into TG‐rich VLDL particles, and hepatic lipoprotein secretion. Drugs with these dual effects may be more steatogenic than drugs acting only on β‐oxidation or only MTP.Keywords
This publication has 35 references indexed in Scilit:
- Nonalcoholic fatty liver diseaseGastroenterology, 2002
- Mitochondria in SteatohepatitisSeminars in Liver Disease, 2001
- Proteasome-mediated Degradation of Apolipoprotein B Targets Both Nascent Peptides Cotranslationally Before Translocation and Full-length Apolipoprotein B After Translocation into the Endoplasmic ReticulumJournal of Biological Chemistry, 1998
- Inhibition of mitochondrial beta-oxidation as a mechanism of hepatotoxicityPharmacology & Therapeutics, 1995
- Evaluation of human blood lymphocytes as a model to study the effects of drugs on human mitochondriaBiochemical Pharmacology, 1993
- Effects of various tetracycline derivatives on in vitro and in vivo β-oxidation of fatty acids, egress of triglycerides from the liver, accumulation of hepatic triglycerides, and mortality in miceBiochemical Pharmacology, 1991
- Tianeptine, a new tricyclic antidepressant metabolized by β-oxidation of its heptanoic side chain, inhibits the mitochondrial oxidation of medium and short chain fatty acids in miceBiochemical Pharmacology, 1989
- Investigation into the mechanism of tetracycline-induced steatosis: Study in isolated hepatocytesToxicology and Applied Pharmacology, 1989
- Inhibition of the mitochondrial oxidation of fatty acids by tetracycline in mice and in man: Possible role in microvesicular steatosis induced by this antibioticHepatology, 1988
- Fatty Liver Induced by Tetracycline in the RatGastroenterology, 1975